*Yuji Yamada1, Tomiki Sumiyoshi2 (1. National Center of Neurology and Psychiatry, 2. National Center of Neurology and Psychiatry)
Session information
Oral
[3O06e2] Schizophrenia
Sat. Jul 2, 2022 5:10 PM - 6:25 PM Room 6 (Conference Building B3・4 (Okinawa Convention Center))
Chair: Nobuyuki Takei
*Keiko Ikemoto1 (1. Iwaki City Medical Center)
*Yuriko Iwakura1,2, Ryoka Kawahara-Miki3, Satoshi Kida4,5, Hidekazu Sotoyama2, Ramil Gabdulkhaev6, Hitoshi Takahashi6, Yasuto Kunii7,8, Mizuki Hino7,8, Atsuko Nagaoka7, Ryuta Izumi7, Risa Shishido7, Toshiyuki Someya9, Hirooki Yabe7, Akiyoshi Kakita6, Hiroyuki Nawa10,2 (1. 新潟大学脳研究所腫瘍病態学分野、2. 新潟大学脳研究所分子神経生物学分野、3. 東京農業大学生物資源ゲノム解析センター、4. 東京大学大学院農学生命科学研究科、5. 東京農業大学生命科学部バイオサイエンス学科、6. 新潟大学脳研究所病理学分野、7. 福島県立医科大学医学部神経精神医学講座、8. 東北大学災害科学国際研究所災害精神医学分野、9. 新潟大学大学院医歯学総合研究科精神医学分野、10. 和歌山県立医科大学生体機能解析学研究室)
*Charalampos Brakatselos1, George Ntoulas1, Michail Zois Asprogerakas1, Olga Tsarna1, Alexia Polissidis2, Joana Silva3, Ioannis Sotiropoulos3, Joao Filipe Oliveira3, Katerina Antoniou1 (1. Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece, 2. Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Efesiou Str, 11527 Athens, Greece, 3. Life and Health Sciences Research Institute (ICVS), University of Minho, Braga, Portugal ICVS/3B’s, PT Government Associate Laboratory, Braga, Portugal)
*Felisa Maria Herrero1, Joel Gruchot2, Hervé Perron3,4, Patrick Küry2, Ulrike Weber-Stadlbauer1,5, Urs Meyer1,5 (1. Institute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich, Switzerland, 2. Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, 3. GeNeuro, 3, Chemin du pré Fleuri 1228 Plan-les-Ouates, Geneva, Switzerland, 4. Université de Lyon-UCBL, Lyon, France, 5. Neuroscience Center Zurich, Zurich, Switzerland)